Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The DNA damage response (DDR) pathway and its core component tumor suppressor p53 block cell cycle progression after genotoxic stress and represent an intrinsic barrier preventing cancer development. The serine/threonine phosphatase PPM1D/Wip1 inactivates p53 and promotes termination of the DDR pathway. Wip1 has been suggested to act as an oncogene in a subset of tumors that retain wild-type p53. In this paper, we have identified novel gain-of-function mutations in exon 6 of PPM1D that result in expression of C-terminally truncated Wip1. Remarkably, mutations in PPM1D are present not only in the tumors but also in other tissues of breast and colorectal cancer patients, indicating that they arise early in development or affect the germline. We show that mutations in PPM1D affect the DDR pathway and propose that they could predispose to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The PPM1D gene is mutated in selected cancer cell lines. (A) Whole-cell lysates from indicated cell lines were probed with anti-Wip1 (Bethyl Laboratories, Inc.), anti-Wip1 (Santa Cruz Biotechnology, Inc. [SC]), and anti–14-3-3 (loading control) antibodies. Note the additional Wip1-reactive band around 60 kD in U2OS and HCT116 cells. PC3 cells are p53 negative and served as a control. (B) Wip1 was depleted in U2OS and HCT116 cells by siRNA, and lysates were probed with the indicated antibodies. (C) Sequencing chromatograms of PPM1D from genomic DNA isolated from U2OS and HCT116 cells. Numbering is based on NCBI GenBank reference sequence NT_010783.15. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence.](https://figures.cochat.ai/paper-figures/a55e0889191c480d83b569a3230ebde9/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-1.jpg)

![Figure 3. Truncated Wip1 mutants show increased protein stability. (A) HCT116 and U2OS cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed using the monoclonal anti-Wip1 antibody (Santa Cruz Biotechnology, Inc. [SC]). (B) Signal intensity corresponding to the FL-Wip1 and truncated Wip1 from A was quantified using ImageJ software. The relative change in signal intensity is shown. Statistical significance was determined by unpaired two-tailed t test (n = 3; *, P < 0.05). (C) U2OS cells were treated with cycloheximide, proteasomal inhibitor MG132 or a combination of both for the indicated times and analyzed as in A. (D) U2OS cells were transfected with plasmid DNA coding for EGFP or EGFP fused to the C-terminal region of Wip1 (aa 380–605). Cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed with an anti-GFP antibody, and the signal intensity was quantified using ImageJ software. n = 3. Error bars indicate standard deviations. exp., exposure.](https://figures.cochat.ai/paper-figures/1244c669d3094b87aac15d5705c32b4a/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this p53/pRb proficient cell line, p21 induction is impaired due to inefficient ATM response 72 and, probably, mutation of the Wip1 phosphatase that interferes with p53 activation.97”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 2×
“Although high doses of DNA damage (such as therapeutic irradiation or radiomimetic drugs) lead to p53-induced programmed cell death or permanent withdrawal from the cell cycle (senescence), more moderate DNA damage (originating from erroneous DNA metabolism or from environmental factors) triggers expression of DNA rep…”
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“The most common example of such DDR defect is an inactivating somatic mutation in the TP53 gene that disables proper response to genotoxic stress, leads to genomic instability, and is found in about half of human tumors (Hollstein et al., 1991).”
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In general, genotoxic stress induces stabilization, oligomerization, and binding of p53 to promoters, causing a widespread modulation of gene expression (Vogelstein et al., 2000).”
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 2×
“…ATM (ataxia telangiectasia mutated)/Chk2, ATR (ataxia telangiectasia and Rad3 related)/Chk1, and p38/ MK2 kinases converges on the tumor suppressor p53, which plays a central role in regulating cell fate decisions in response to genotoxic stress (Jackson and Bartek, 2009; Medema and Macůrek, 2012).”
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“Whereas tumor development is substantially boosted by inactivation of the second allele of the tumor suppressor genes, monoallelic gain-offunction mutations are usually sufficient to activate oncogenes (Vogelstein and Kinzler, 2004).”
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 2×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression
Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.033 · Cited by 2,173 · cited 2×
“A stable cell line expressing the fluorescent, ubiquitination-based cell cycle indicator (FUCCI) was generated by transduction of HCT116 cells with pCSII-EF-MCS-mKO2hCdt1(30–120) and pCSII-EF-MCS-mAG-hGeminin(1–110) plasmids (Sakaue-Sawano et al., 2008) followed by FACS sorting of double-positive cells from which a si…”
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966 · cited 1×
“For example, germline mutations of oncogenic tyrosine kinases RET, MET, and KIT are linked with medullary thyroid carcinoma, hereditary papillary renal carcinoma, and hereditary gastrointestinal stromal tumor syndrome, respectively (Mulligan et al., 1993; Schmidt et al., 1997; Nishida et al., 1998).”
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
“Germline PPM1D mutations are associated with breast and ovarian cancer predisposition and may impair p53 function (Kleiblova et al., 2013).”
Backgroundthe St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
“PPM1D mutations were primarily protein-truncating variants in exon 6; these mutations have previously been demonstrated as gain-of-function mutations that lead to impaired TP53 function (Figure 1E) (Kleiblova et al., 2013).”
Background
Metadata
- Authors
- Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., Medema, R. H., & Macurek, L.
- Affiliations
- Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ-12853 Prague, Czech Republic 1
- Division of Cell Biology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands 2
- Czech Academy of Sciences (CZ)
- Charles University (CZ)
- University Medical Center Utrecht (NL)
- Department of Cancer Cell Biology 4 and 5
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Medema, René H.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2013-05-06
- Volume
- 201
- Issue
- 4
- Pages
- 511-521
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC3653305
- OpenAlex
- W2096812573
- Cited by
- 170
- References
- 39
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 25 · 2023: 12 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 11 · 2017: 13 · 2016: 12 · 2015: 11 · 2014: 17 · 2013: 5
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Cell Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- ASEP (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- PPM1D, Wip1, gain-of-function mutations, p53, G1/S checkpoint, DNA damage response, tumor suppressor inactivation, breast cancer, colorectal cancer, germline mutations, cancer susceptibility, cell cycle arrest
- MeSH terms
- Protein Phosphatase 2C, Cell Cycle, DNA Damage, HeLa Cells, Humans, Mutation, Neoplasms, Phosphoprotein Phosphatases, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G1 Phase, Genetic Predisposition to Disease, Cell Line, Tumor, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. https://app.cochat.ai/papers/10.1083/jcb.201210031
- The paper
- Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., Medema, R. H., & Macurek, L. (2013). Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. Journal of Cell Biology. https://doi.org/10.1083/jcb.201210031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.